1-(4-氟苯基)吡唑-4-甲酸 | 138907-81-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(4-氟苯基)吡唑-4-甲酸
• 英文名称: 1-(4-fluorophenyl)-1H-pyrazole-4-carboxylic acid
• 英文别名: 1-(4-fluorophenyl)pyrazole-4-carboxylic acid
• CAS: 138907-81-0
• 化学式: C₁₀H₇FN₂O₂
• mdl: MFCD07186399
• 分子量: 206.176
• InChiKey: VHGLETHNIUVDGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-(4-氟苯基)吡唑-4-甲酸 在 氯化亚砜 作用下， 以 吡啶 、 1,2-二氯乙烷 为溶剂， 反应 2.0h， 生成 N-{3-cyano-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl}-1-(4-fluorophenyl)pyrrolecarboxamide
  参考文献：
  名称：

  AMIDE COMPOUNDS AND MEDICINAL USE THEREOF

  摘要：

  公开号：

  EP1176140B1
• 作为产物：
  描述：

  5-氨基-1-(4-氟苯)吡唑-4-羧酸乙酯 在 亚硝酸特丁酯 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 24.0h， 生成 1-(4-氟苯基)吡唑-4-甲酸
  参考文献：
  名称：

  Synthesis of Pyrazole-Carboxamides and Pyrazole-Carboxylic Acids Derivatives: Simple Methods to Access Powerful Building Blocks

  摘要：

  摘要：含有吡唑基团的混合系统展示了广泛的生物活性。为了获得含有吡唑环的新型混合物，本研究合成了二十种吡唑羧酸和二十种吡唑羧酰胺，采用简单的合成方法，作为开发新结构的基础。

  DOI：

  10.2174/1570178617999200728215322

文献信息

• [EN] SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME<br/>[FR] AMIDES TRICYCLIQUES SUBSTITUÉS, ANALOGUES DE CEUX-CI ET PROCÉDÉS LES METTANT EN OEUVRE
  申请人：ARBUTUS BIOPHARMA CORP

  公开号：WO2021229302A1

  公开（公告）日：2021-11-18

  The present disclosure includes substituted tricyclic amides, or analogues thereof of formula (I) (I), wherein X, Y, ring A, R1, R5, R6 and R7 are as defined herein, and compositions comprising compounds of formula (I) that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

  本公开涵盖了替代三环酰胺，或其类似物的化合物，其化学式为(I)，其中X、Y、环A、R1、R5、R6和R7如本文所定义，并包括化合物(I)的组合物，可用于治疗或预防患者体内的乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HDV）感染。
• SUBSTITUTED BENZAMIDE DERIVATIVES
  申请人：Galley Guido

  公开号：US20120316165A1

  公开（公告）日：2012-12-13

  The present invention relates to compounds of formula wherein R 1 , R 2 , R 3 , X, Z, Ar, and n are as described in the claims, Ar is phenyl or heteroaryl, selected from the group consisting of 1H-indazole-3yl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, pyrimidine-5-yl, 1H-pyrazole-3-yl, 1H-pyrazole-4-yl and 1H-pyrazole-5-yl; or to a pharmaceutically suitable acid addition salt thereof, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及以下式中的化合物，其中R1、R2、R3、X、Z、Ar和n如索权所述，Ar为苯基或杂环芳基，所述杂环芳基选自以下群体：1H-吲哚基、吡啶-2-基、吡啶-3-基、吡啶-4-基、嘧啶-5-基、1H-吡唑-3-基、1H-吡唑-4-基和1H-吡唑-5-基；或其药学上适用的酸加盐，可用于治疗抑郁症、焦虑障碍、躁郁症、注意力缺陷多动障碍（ADHD）、与压力相关的障碍、精神障碍、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用、代谢障碍、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。
• [EN] SUBSTITUTED BENZAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZAMIDE SUBSTITUÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012168265A1

  公开（公告）日：2012-12-13

  The present invention relates to compounds of formula (I) wherein R1 is hydrogen, halogen, cyano, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen or C(O)NH2, or is phenyl optionally substituted by halogen, cyano or lower alkoxy substituted by halogen, or is 2,2-difluorobenzo[d][1,3]dioxol-5-yl, or is 6-(trifluoromethyl)pyrazin-2-yl or 5-(trifluoromethyl)pyrazin-2-yl or is 6-(trifluoromethyl)pyrimidin-4-yl, or is 6- (trifluoromethyl)pyridin-3-yl, or is 5-cyanopyrazin-2-yl or is 2- (trifluoromethyl)pyrimidin-4-yl; n is 1 or 2 R2 is halogen, lower alkyl or cyano and R3 is hydrogen, or R2 is hydrogen and R3 is halogen, lower alkyl or cyano; X is a bond, -NR'-, -CH2NH- or -CHR'-; R' is hydrogen or lower alkyl; Z is a bond, -CH2- or -O-; Ar is phenyl or is heteroaryl, selected from the group consisting of 1H-indazole-3yl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, pyrimidine-5-yl, lH-pyrazole-3-yl, 1H- pyrazole-4-yl or lH-pyrazole-5-yl; or to a pharmaceutically suitable acid addition salt thereof, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及以下化合物，其化学式为（I）其中R1为氢、卤素、氰基、较低的烷基、卤素取代的较低烷基、较低的烷氧基、卤素取代的较低烷氧基或C（O）NH2，或为苯基，可选择地被卤素、氰基或卤素取代的较低烷氧基取代，或为2,2-二氟苯并[d][1,3]二噁唑-5-基，或为6-（三氟甲基）吡嗪-2-基或5-（三氟甲基）吡嗪-2-基或6-（三氟甲基）嘧啶-4-基，或为6-（三氟甲基）吡啶-3-基，或为5-氰基吡嗪-2-基或为2-（三氟甲基）嘧啶-4-基；n为1或2，R2为卤素、较低烷基或氰基，R3为氢，或R2为氢，R3为卤素、较低烷基或氰基；X为键，-NR'-，- NH-或-CHR'-；R'为氢或较低烷基；Z为键，-CH2-或-O-；Ar为苯基或杂环芳基，选自由1H-吲唑-3-基、吡啶-2-基、吡啶-3-基、吡啶-4-基、嘧啶-5-基、1H-吡唑-3-基、1H-吡唑-4-基或1H-吡唑-5-基；或其药学上适宜的酸盐，可用于治疗抑郁症、焦虑症、躁郁症、注意缺陷多动障碍（ADHD）、与压力相关的疾病、精神疾病、精神分裂症、神经疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用、代谢紊乱、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的治疗。
• [EN] PYRAZINE AND IMIDAZOLIDINE DERIVATIVES AND THEIR USES TO TREAT HEPATITIS C<br/>[FR] DÉRIVÉS DE PYRAZINE ET D'IMIDAZOLIDINE ET LEURS UTILISATIONS EN VUE DU TRAITEMENT DE L'HÉPATITE C
  申请人：GILEAD PHARMASSET LLC

  公开号：WO2012103113A1

  公开（公告）日：2012-08-02

  Disclosed herein are compounds useful for treating a viral infection, such HCV.

  本文披露了一些用于治疗病毒感染，如HCV的化合物。
• [EN] PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE<br/>[FR] DÉRIVÉS DE PYRAZOLE-CARBOXAMIDE EN TANT QUE MODULATEURS DE TAAR POUR UTILISATION DANS LE TRAITEMENT DE PLUSIEURS TROUBLES, TELS QUE LA DÉPRESSION, LE DIABÈTE ET LA MALADIE DE PARKINSON
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014041007A1

  公开（公告）日：2014-03-20

  The present invention relates to compounds of formula (I) wherein R1 is phenyl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkoxy, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, lower alkoxy substituted by halogen or lower alkoxy substituted by hydroxy; or is pyridine-2, 3 or 4-yl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, lower alkoxy, lower alkoxy substituted by halogen or lower alkoxy substituted by hydroxyl; or is pyrimidin-2, 4 or 5-yl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkyl substituted by hydroxy or lower alkyl substituted by halogen; or is pyrazin-2-yl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy or cyano; or is 2,2-difluorobenzo[d][l,3]dioxol-5-yl, or is thiazolyl, optionally substituted by lower alkyl substituted by halogen; R2 is hydrogen or lower alkyl; R3 is hydrogen, amino or lower alkyl; Z is a bond, -CH2- or -O-; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formulas I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及以下式（I）的化合物，其中R1是苯基，可以被卤素、较低烷基、较低环烷基、较低烷氧基、氰基、被卤素取代的较低烷基、被羟基取代的较低烷基、被卤素取代的较低烷氧基或被羟基取代的较低烷氧基；或是吡啶-2、3或4-基，可以被卤素、较低烷基、较低环烷基、氰基、被卤素取代的较低烷基、被羟基取代的较低烷基、较低烷氧基、被卤素取代的较低烷氧基或被羟基取代的较低烷氧基取代；或是嘧啶-2、4或5-基，可以被卤素、较低烷基、较低环烷基、被羟基取代的较低烷基或被卤素取代的较低烷基取代；或是吡嗪-2-基，可以被卤素、较低烷基、较低环烷基、被卤素取代的较低烷基、被羟基取代的较低烷基或氰基取代；或是2,2-二氟苯并[d][1,3]二氧杂环-5-基，或是噻唑基，可以被被卤素取代的较低烷基取代；R2是氢或较低烷基；R3是氢、氨基或较低烷基；Z是键，-CH2-或-O-；或其药学上适用的酸盐。现已发现，式I的化合物对追踪胺相关受体（TAARs）有很好的亲和力，尤其是对TAAR1。这些化合物可用于治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍（ADHD）、与压力相关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用以及代谢障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。